Why the study?
Is the ReAces puncturable transcatheter atrial septal defect occluder safe, effective, and feasible for subsequent septal puncture in subjects with secundum atrial septal defect?
Is the ReAces puncturable transcatheter atrial septal defect occluder safe, effective, and feasible for subsequent septal puncture in subjects with secundum atrial septal defect?
The novel ReAces puncturable ASD occluder demonstrates 100% acute procedural success in early animal and human testing, while preserving the ability to perform future transseptal puncture.
Initial experience suggests feasibility of puncturable ASD occluders; leaves open durability, safety, and need for larger trials.
ReAces is a novel puncturable transcatheter atrial septal defect occluder. The device success rate was 100% (n = 14 of 14) in the animal experiment. Four swine successfully received puncture of the device 60 days after implantation of the device. The acute procedure success rate in the 10 patients was 100%. Transthoracic echocardiography examination showed that the devices were well positioned with no residual shunt, and the area of central portion of occluder was substantially thin. It is safe and effective to use ReAces for closure of secundum atrial septal defect, and puncture the atrial septum at the portion of the device is feasible.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) studied secundum atrial septal defect (n=10). ReAces puncturable transcatheter atrial septal defect occluder was evaluated on acute procedure success rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: